



Q3 2007-08 Quarterly Results

TOTAL INCOME Rs.549.42 Crs; NET PROFIT Rs.55.25 Crs

Aurobindo Pharma is pleased to report its Q3 financials:

Q3 Standalone Financials:

Total Income Rs.549.42 Crs. (Rs.511.86 Crs.), the EBITDA Rs.93.58 Crs. (Rs.90.49 Crs.) and Net Profit Rs.55.25 Crs. (Rs.60.12 Crs.).

The sales in Q3 were impacted mainly due to lower off take of SSP products on account of fluctuation in Pen-G prices and continued appreciation of Rupee Vs USD.

The Company has completed the transfer of product Dossiers/IPRs to its European Subsidiary. Consequently there is increased provision for the tax. The benefits of globalization of IPRs will accrue in the coming years.

For the nine months ended 31st December 2007, the Total Income, EBITDA and Net Profit stand at Rs.1711.53 Crs (1395.71), Rs.325.82 Crs (241.34) and Rs.214.70 Crs (150.97) respectively.

Q3 Consolidated Financials:

During the Quarter ended 31st December 2007, the company has achieved Consolidated Total Income, EBITDA and PAT of Rs.587.08 Crs, Rs.96.31 Crs & Rs.44.57 Crs respectively.

For the nine months ended 31st December 2007, the Total Income, EBITDA and Net Profit stand at Rs.1808.30 Crs, Rs.319.71 Crs and Rs.168.37 Crs respectively.

The other income in Q3 includes exchange fluctuation gain of Rs.9.53 Crs, sales of Dossiers Rs.2.81 Crs and balance miscellaneous income. Similarly other income in Q2 and Q1 includes exchange fluctuation gain of Rs.22.57 Crs ad Rs.29.39 Crs, sales of Dossiers Rs.1.81 Crs and Rs.3.3 Crs respectively.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has received approvals for several facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar
Ameerpet, Hyderabad
Phone: 040-66725000
Email: ir@aurobindo.com